Stock listing

Stuttgart:ZVA Cellectis S.A. Aktie

German listing (Stuttgart) of Cellectis S.A. · home listing Euronext:ALCLS

Follow Cellectis S.A. into a list and get an email when it puts out news.

Home listing price · EURONEXT:ALCLS

€0.91 EUR -0.08 (-8.0%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, EURONEXT:ALCLS

Past year -78.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
€0.903 – €0.999 EURNov 20, 2026
Volume
285,262 sharesNov 20, 2026
Market cap
€66.19M EURAt the close on Nov 20, 2026 · price × 72.73M shares outstanding
52-week range
€0.895 – €4.75 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
€617,767 EURMedian day 272,243 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Cellectis S.A. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
Euronext:ALCLS · Home€0.91 EUR-0.079 (-8.0%)285,262€0.999€0.999€0.903€0.989Close on Nov 20, 2026
NASDAQ:CLLS$0.921 USD-0.063 (-6.4%)52,626$0.990$0.996$0.903$0.984Close on Nov 20, 2026
OTC:CMVLF$1.014 USD+0.022 (+2.2%)4,000$1.014$1.014$1.014$0.992Close on Nov 20, 2026
Frankfurt:ZVAA€0.855 EUR-0.040 (-4.5%)—€0.855€0.855€0.855€0.895Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · EURONEXT:ALCLS · EUR, adjusted for splits

DayCloseChange%OpenHighLowVolume
€0.91-0.079-8.0%€0.999€0.999€0.903285,262
€0.989-0.024-2.4%€1.058€1.058€0.977159,201
€1.013+0.013+1.3%€1.001€1.069€0.955489,656
€1.00-0.056-5.3%€1.05€1.10€1.00320,365
€1.056-0.224-17.5%€1.07€1.17€1.011,980,513
€1.28-0.071-5.3%€1.30€1.376€1.201,268,732
€1.351+0.302+28.8%€1.088€1.351€1.0471,607,758
€1.049-0.002-0.2%€1.005€1.095€1.005340,407
€1.051+0.046+4.6%€1.029€1.057€1.00274,413
€1.005-0.043-4.1%€1.002€1.047€0.981145,483
€1.048+0.02+1.9%€1.072€1.089€1.011337,007
€1.028-0.013-1.2%€1.04€1.076€1.013230,372
€1.041+0.061+6.2%€0.999€1.066€0.952351,521
€0.98-0.058-5.6%€0.954€1.009€0.947239,611
€1.038-0.064-5.8%€1.14€1.14€1.026337,053
€1.102-0.026-2.3%€1.14€1.167€1.088501,285
€1.128+0.153+15.8%€0.984€1.19€0.981,147,028
€0.975+0.036+3.8%€0.973€0.979€0.895522,092
€0.9390.000.0%€0.96€0.964€0.936105,247
€0.939-0.008-0.8%€0.988€0.988€0.926155,909
€0.947-0.048-4.9%€0.976€0.976€0.932291,553
€0.995+0.045+4.8%€0.915€1.048€0.915466,148
€0.95-0.002-0.2%€0.942€0.958€0.908626,558
€0.952-0.081-7.9%€1.014€1.014€0.942553,162
€1.033-0.01-1.0%€1.069€1.083€1.021108,181
€1.043-0.029-2.7%€1.105€1.105€1.038226,054
€1.072+0.022+2.1%€1.056€1.11€1.05303,598
€1.05-0.089-7.8%€1.13€1.13€1.04588,187
€1.139+0.011+1.0%€1.127€1.185€1.127152,505
€1.128+0.002+0.2%€1.12€1.159€1.11288,681
€1.126-0.102-8.3%€1.19€1.192€1.111352,532
€1.228-0.02-1.6%€1.23€1.25€1.182184,226
€1.248-0.001-0.1%€1.255€1.311€1.201184,937
€1.249-0.005-0.4%€1.255€1.285€1.225175,484
€1.254-0.036-2.8%€1.277€1.282€1.23271,580
€1.29-0.045-3.4%€1.30€1.322€1.27289,299
€1.335+0.064+5.0%€1.29€1.365€1.255652,521
€1.271-0.008-0.6%€1.257€1.309€1.228430,994
€1.279+0.031+2.5%€1.268€1.30€1.258253,875
€1.248+0.033+2.7%€1.238€1.257€1.208176,646
€1.215-0.025-2.0%€1.227€1.248€1.192258,051
€1.24-0.151-10.9%€1.36€1.392€1.224760,288
€1.391+0.067+5.1%€1.334€1.447€1.301634,839
€1.324+0.013+1.0%€1.339€1.374€1.275506,539
€1.311+0.089+7.3%€1.274€1.38€1.1881,069,350
€1.222+0.071+6.2%€1.101€1.305€1.0931,834,240
€1.151-0.199-14.7%€1.298€1.34€1.1512,067,466
€1.35-0.155-10.3%€1.548€1.68€1.262,664,311
€1.505-1.129-42.9%€1.762€1.79€1.4441,356,429
€2.634-0.104-3.8%€2.72€2.746€2.62129,898
€2.738-0.002-0.1%€2.736€2.844€2.72264,220
€2.74-0.08-2.8%€2.764€2.784€2.69141,892
€2.82-0.09-3.1%€2.91€2.91€2.796152,104
€2.91+0.106+3.8%€2.868€2.956€2.81288,762
€2.804-0.144-4.9%€2.94€2.994€2.80482,746
€2.948+0.106+3.7%€2.822€2.994€2.822119,861
€2.842-0.008-0.3%€2.92€3.028€2.802134,932
€2.85-0.084-2.9%€2.89€2.918€2.75177,049
€2.934-0.108-3.6%€3.10€3.11€2.902109,092
€3.042-0.058-1.9%€3.08€3.15€2.98177,292
€3.10+0.07+2.3%€3.00€3.16€3.00272,906
€3.03+0.092+3.1%€2.938€3.086€2.91256,077
€2.938+0.182+6.6%€2.70€2.938€2.7088,600
€2.756-0.114-4.0%€2.858€2.884€2.73483,162
€2.87-0.09-3.0%€2.90€2.97€2.85882,146
€2.96+0.216+7.9%€2.768€2.976€2.768356,645

Splits

1 split · EURONEXT:ALCLS · every price before a split is adjusted for it

DayRatioWhat
2-for-1Split
Ticker
Stuttgart:ZVA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Stuttgart
Currency
EUR

What changed lately

Latest news

All Cellectis S.A. news

Cellectis S.A. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
31 in the last 12 months · 47 in all · newest Nov 13, 2026 · oldest 2025
Calls
12 calls with a replay · 12 with a transcript · latest May 11, 2026
Decks
35 decks · latest November 2026

Where Cellectis S.A. is listed

ListingExchangeCountryCurrency
Euronext:ALCLS · Home listingEuronextFranceEUR
NASDAQ:CLLSNASDAQUnited StatesUSD
gettex:ZVAgettexGermanyEUR
LS Exchange:A0MKPRLS ExchangeGermanyEUR
LSIN:0WA2LSINUnited KingdomEUR
Lang & Schwarz:A0MKPRLang & SchwarzGermanyEUR
Tradegate:ZVATradegateGermanyEUR
BOATS:CLLSBOATSUnited StatesUSD
gettex:ZVAAgettexGermanyEUR
Lang & Schwarz:A14QZELang & SchwarzGermanyEUR
Munich:ZVAMunichGermanyEUR
Hamburg:ZVAHamburgGermanyEUR
OTC:CMVLFOTCUnited StatesUSD
Tradegate:ZVAATradegateGermanyEUR
Aquis:ALCLSPAquisUnited KingdomEUR
Aquis:ALCLSPAquisUnited KingdomEUR
Dusseldorf:ZVADusseldorfGermanyEUR
Dusseldorf:ZVAADusseldorfGermanyEUR
Frankfurt:ZVAFrankfurtGermanyEUR
Frankfurt:ZVAAFrankfurtGermanyEUR
LS Exchange:A14QZELS ExchangeGermanyEUR
Stuttgart:ZVA · This pageStuttgartGermanyEUR
Stuttgart:ZVAAStuttgartGermanyEUR
Turquoise:ALCLSPTurquoiseUnited KingdomEUR

Valuation

EV/sales −0.2× against a median of 74.5×: the lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
−€8.78M EUR
P/E
Loss
EV/sales
−0.2×
EV/EBITDA
Negative EBITDA
Price/book
1.8×
Gross margin
74.7%
Operating margin
−107.9%
Net margin
−115.4%
Debt to equity
2.1×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Cellectis S.A. · EURONEXT:ALCLSUS$72.64M−US$9.64Mn/a−0.2×n/a1.8×−115.4%2.1×n/a
Recce Pharmaceuticals Ltd. · ASX:RCEUS$75.90MUS$81.02Mn/an/an/an/an/an/an/a
Black Diamond Therapeutics, Inc. · NASDAQ:BDTXUS$75.28M−US$10.71Mn/an/an/a0.8×n/a0.2×1.76
Great Novel Therapeutics Biotech & Medicals Corp. · TPEX:7427US$73.93MUS$52.73Mn/a1,442×n/a3.2×n/a0.0×n/a
Pentixapharm Holding AG · XETR:PTPUS$73.87MUS$69.92Mn/a1,158×n/a2.4×n/a0.0×n/a
Dimerix Limited · ASX:DXBUS$73.52MUS$62.98Mn/a21.9×n/an/a−685.3%n/an/a
Faron Pharmaceuticals Oy · LSE:FARNUS$72.99MUS$57.36Mn/an/an/a5.7×n/a1.5×n/a
Kanaph Therapeutics Inc. · KRX:0082N0US$72.81MUS$39.07Mn/a9.3×n/a2.1×−729.8%0.0×n/a
Eastwood Bio-Medical Canada Inc · TSXV:EBMUS$72.06MUS$72.05Mn/a127×n/an/a−28.5%n/a0.56
SynAct Pharma AB · OMXSTO:SYNACTUS$71.20MUS$71.51Mn/an/an/a5.1×n/a0.3×n/a
Bioton S.A. · GPW:BIOUS$70.63MUS$86.88Mn/a1.4×6.5×0.5×−3.3%0.1×n/a
Median of the othersUS$73.25MUS$66.45M74.5×6.5×2.4×−356.9%0.1×1.16

Forecasts

Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
6.50 EUR · Analysts' mean
EPS, year to Dec 2026
-0.74 · 1 analyst
Revenue, year to Dec 2026
56.24M · 3 analysts

Team and board

Officers

OfficerRole
André ChoulikaChief Executive Officer & Director
Patricia Sosa NavarroChief of Staff to the CEO
Arthur StrilChief Financial Officer & Chief Business Officer
Marie-Bleuenn TerrierGeneral Counsel
David SourdiveExecutive Vice President CMC & Manufacturing and Director
Kyung Nam-WortmanExecutive Vice President, Chief Human Resources Officer
Steve DoaresSenior Vice President, US Manufacturing and Site Head
Adrian KilcoyneChief Medical Officer
Philippe DuchateauChief Scientific Officer
Stephan ReynierChief Regulatory and Pharmaceutical Compliance Officer

Board

DirectorRole
Jean-Pierre GarnierChairman of the Board of Directors - Director
André ChoulikaChief Executive Officer & Director
David SourdiveExecutive Vice President CMC & Manufacturing and Director

Events

Next results
Mar 18, 2027 (expected)

Calls

CallWhenStatus
Cellectis (Euronext:ALCLS) Q1 2026 Earnings CallMon, May 11, 2026Replay
Cellectis (Euronext:ALCLS) Q4 2025 Earnings CallFri, Mar 20, 2026 · 8:00 AM ETReplay
Cellectis (Euronext:ALCLS) Q2 2025 Earnings CallTue, Aug 05, 2025 · 8:00 AM ETReplay
Cellectis (Euronext:ALCLS) Q4 2024 Earnings CallFri, Mar 14, 2025 · 8:00 AM ETReplay
Cellectis (Euronext:ALCLS) Q1 2024 Earnings CallWed, May 29, 2024 · 8:00 AM ETReplay
Cellectis (Euronext:ALCLS) Q3 2023 Earnings CallTue, Nov 07, 2023 · 8:00 AM ETReplay
Cellectis (Euronext:ALCLS) Q2 2023 Earnings CallFri, Aug 04, 2023 · 8:00 AM ETReplay
Cellectis (Euronext:ALCLS) Q1 2023 Earnings CallFri, May 05, 2023 · 8:00 AM ETReplay
Cellectis (Euronext:ALCLS) Q4 2022 Earnings CallThu, Mar 09, 2023 · 8:00 AM ETReplay
Cellectis (Euronext:ALCLS) Q3 2022 Earnings CallFri, Nov 04, 2022 · 8:00 AM ETReplay
All 12 calls
CallWhenStatus
Cellectis (Euronext:ALCLS) Q2 2022 Earnings CallFri, Aug 05, 2022 · 8:00 AM ETReplay
Cellectis (Euronext:ALCLS) Q4 2021 Earnings CallFri, Mar 04, 2022 · 8:00 AM ETReplay

Results days

QuarterResultsShare move
Quarter to Sep 30, 2026Nov 12, 2026 · After close−17.5%
Q2 2026Aug 6, 2026 · After close−0.5%
Q1 2026May 11, 2026 · After close+1.7%
Q4 2025Mar 19, 2026 · After close−1.4%
Q3 2025Nov 7, 2025 · After close+12.2%
Q2 2025Aug 4, 2025 · After close−15.1%
Q1 2025May 12, 2025 · After close−1.3%
Q4 2024Mar 13, 2025 · After close−1.9%
Q3 2024Nov 4, 2024 · After close−1.5%
Q2 2024Aug 6, 2024 · After close+3.0%
All 20 quarters
QuarterResultsShare move
Q1 2024Apr 29, 2024 · After close−0.6%
Q4 2023Mar 13, 2024 · After close−1.2%
Q3 2023Nov 6, 2023 · After close−1.8%
Q2 2023Aug 3, 2023 · After close−1.6%
Q1 2023May 4, 2023 · After close+1.7%
Q4 2022Mar 8, 2023 · After close−3.1%
Q3 2022Nov 3, 2022 · After close−5.7%
Q2 2022Aug 4, 2022 · After close+9.4%
Q1 2022May 12, 2022 · After close+1.6%
Q4 2021Mar 3, 2022 · After close−3.2%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck35 slidesNovember 2026
Corporate Update (September 2026)Corporate update40 slidesSep 14, 2026
Corporate Update (September 2026)Corporate update40 slidesSep 14, 2026
Corporate Update (September 2026)Corporate update41 slidesSep 14, 2026
EHA 2026Conference23 slidesJun 15, 2026
Investor Day (June 2026)Investor day65 slidesJune 2026
Q1 2026 Earnings PresentationEarnings31 slidesMay 11, 2026
Investor Presentation (May 2026)Investor deck31 slidesMay 2026
Investor Presentation (November 2025)Investor deck32 slidesNovember 2025
Investor Day (October 2025)Investor day65 slidesOct 17, 2025
All 35 decks
DeckKindSlidesDate
Investor Presentation (October 2025)Investor deck25 slidesOctober 2025
Investor Presentation (August 2025)Investor deck25 slidesAugust 2025
Investor Presentation (May 2025)Investor deck25 slidesMay 2025
Investor Presentation (March 2025)Investor deck25 slidesMarch 2025
Investor Presentation (August 2024)Investor deck36 slidesAugust 2024
Investor Presentation (May 2024)Investor deck36 slidesMay 2024
Technical Presentation (2023)Technical16 slidesNov 7, 2023
Investor Presentation (August 2023)Investor deck31 slidesAugust 2023
Investor Presentation (June 2023)Investor deck31 slidesJune 2023
Investor Presentation (March 2023)Investor deck34 slidesMarch 2023
Technical Presentation (December 2022)Technical16 slidesDecember 2022
Corporate Update (December 2022)Corporate update34 slidesDecember 2022
Investor Presentation (January 2022)Investor deck27 slidesJanuary 2022
Investor Presentation (January 2022)Investor deck27 slidesJanuary 2022
Investor Presentation (August 2021)Investor deck32 slidesAugust 2021
Technical Presentation (July 2021)Technical46 slidesJuly 2021
Investor Presentation (June 2021)Investor deck23 slidesJun 10, 2021
Investor Presentation (January 2021)Investor deck19 slidesJanuary 2021
Investor Presentation (December 2020)Investor deck19 slidesDec 15, 2020
Investor Presentation (November 2020)Investor deck19 slidesNov 17, 2020
Investor Presentation (November 2020)Investor deck18 slidesNov 6, 2020
Q4 2019 Earnings PresentationEarnings19 slidesMar 5, 2020
Investor Presentation (September 2019)Investor deck32 slidesSep 10, 2019
Investor Presentation (June 2018)Investor deck29 slidesJune 2018
Investor Presentation (January 2018)Investor deck25 slidesJanuary 2018

Open Decks

IPO

Priced at US$41.50 an ADS on Mar 24, 2015.

Price
US$41.50 an ADS
ADSs offered
5,500,000 American depositary shares
Offering size
US$228.3 million
Underwriters' option
Up to 825,000 more ADSs
Underwriters
BofA Merrill Lynch, Jefferies, Piper Jaffray, Oppenheimer & Co., Trout Capital · In the order on the cover
ADSs delivered
On or about Mar 30, 2015

Steps

StepWhen
Draft sent to the SEC in confidenceDec 19, 2014
Filed publiclyFeb 20, 2015
Amended 4 timesNewest Mar 24, 2015
Shares registered with an exchangeMar 23, 2015
Declared effective by the SECMar 24, 2015
Final prospectus, with the priceMar 26, 2015

Open IPO · From the cover of the final prospectus (424B1) filed Mar 26, 2015

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue72.9M41.5M755.0K19.2M30.3M51.1M15.2M12.7M25.2M44.8M
Cost of revenue00737.0K1.77M1.84M1.95M11.4M2.74M2.62M1.69M
Gross profit55.0M41.5M18.0K17.4M37.7M37.7M3.80M9.99M22.6M40.9M
Research and development93.5M90.5M87.6M97.5M117.8M77.0M92.0M76.6M79.2M78.5M
Selling, general and administrative19.8M19.1M16.8M17.5M22.9M22.5M43.0M47.2M44.8M43.4M
Operating income-33.1M-59.6M-97.3M-89.7M-103.5M-42.3M-123.6M-105.1M-92.7M-67.3M
Depreciation and amortization20.1M19.8M18.5M18.4M14.2M7.83M6.88M2.38M3.37M2.21M
EBITDA-13.0M-39.7M-78.8M-71.2M-89.3M-34.5M-116.7M-102.7M-89.3M-65.1M
Interest expense51.1M21.6M40.6M371.0K368.0K73.0K3.00K39.0K07.10M
Income before tax-68.0M-36.8M-116.5M-98.6M-96.7M-53.6M-115.2M-88.3M-103.7M-67.3M
Income tax-423.0K0371.0K87.0K000000
Net income-67.6M-36.8M-101.1M-106.1M-114.2M-81.1M-102.1M-78.7M-99.4M-67.3M
Earnings per share, basic-0.67-0.41-1.77-2.33-2.55-1.91-2.41-1.93-2.78-1.91
Earnings per share, diluted-0.67-0.41-1.77-2.33-2.55-1.91-2.41-1.93-2.78-1.91

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents61.5M143.3M136.7M93.2M185.6M241.1M340.5M451.5M256.4M254.6M
Short-term investments147.1M117.1M67.1M7.91M499.0K27.1M20.4M388.0K40.6M36.5M
Receivables14.4M6.71M569.0K772.0K20.4M5.17M2.96M2.97M2.75M3.63M
Inventory89.7M001.60M2.90M275.0K250.0K118.0K
Current assets236.2M287.1M233.0M122.0M225.4M315.4M391.5M487.6M323.2M312.5M
Property, plant and equipment38.8M45.9M54.7M63.6M78.8M71.7M23.7M8.73M7.23M16.9M
Goodwill-1.00K1.00K-1.00K0
Total assets324.7M383.5M334.3M261.2M382.1M469.5M467.5M500.8M332.9M331.4M
Accounts payable17.3M18.7M19.1M21.5M23.8M24.6M29.3M15.9M9.46M9.72M
Current liabilities145.8M166.3M155.1M48.1M49.3M52.0M62.6M46.9M45.5M56.2M
Long-term debt51.2M44.0M28.4M20.5M20.0M28.8M46.5M1.02M13.0K29.4K
Total debt90.7M91.5M85.1M82.8M102.2M111.3M47.6M1.35M34.0K1.76M
Total liabilities248.8M252.5M249.6M135.3M145.6M160.6M112.0M50.6M47.0M56.6M
Shareholders' equity75.9M131.0M84.7M118.0M221.3M283.8M315.1M409.3M264.9M272.8M
Shares outstanding100.3M100.1M71.8M45.7M45.5M42.8M42.5M42.4M36.0M35.3M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-39.4M23.0M-24.7M-87.4M-104.6M-80.3M-69.1M-68.1M-52.3M-32.7M
Capital spending-2.36M-2.58M-1.07M-2.43M-18.5M-44.1M-12.9M-4.71M-2.38M-13.7M
Free cash flow-41.8M20.4M-25.8M-89.9M-123.1M-124.3M-82.1M-72.9M-54.7M-46.4M
Cash from investing-29.5M-102.8M-15.5M-2.76M7.28M-54.3M-35.9M35.6M1.78M-53.1M
Cash from financing-16.8M89.1M82.9M1.15M47.5M27.3M-3.86M236.5M41.3M485.0K
Dividends paid000000
Share buybacks44.0K82.8M67.9M-569.0K15.5M9.55M-469.0K186.7M3.05M-137.0K
Change in cash-85.6M9.29M42.6M-89.1M-49.8M-107.3M-108.9M204.0M-9.28M-85.4M

Open Financials

Filings

FilingDateTypeFiled with
Cellectis Reports Third Quarter 2026 Financial Results and Provides a Business UpdateNov 13, 2026ResultsEuronext
6-K · Report of a foreign issuerNov 13, 2026Current reportSEC
6-K · Report of a foreign issuerNov 12, 2026Current reportSEC
6-K · Report of a foreign issuerNov 9, 2026Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 9, 2026Big-stake noticeSEC
Cellectis to Report Third Quarter Financial Results on November 12, 2026Nov 9, 2026ResultsEuronext
Monthly information on share capital and company voting rightsNov 4, 2026Other filingsEuronext
6-K · Report of a foreign issuerOct 28, 2026Current reportSEC
Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026Oct 27, 2026Other filingsEuronext
6-K · Report of a foreign issuerSep 14, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
Cellectis annonce sa transformation stratégique en société d'édition du génome in vivoSep 13, 2026Other filingsEuronext
6-K · Report of a foreign issuerSep 11, 2026Current reportSEC
6-K/A · Report of a foreign issuer, amendedSep 11, 2026Current reportSEC
Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business UpdateSep 10, 2026Operations updateEuronext
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital socialSep 2, 2026Monthly returnEuronext
6-K · Report of a foreign issuerSep 1, 2026Current reportSEC
Cellectis annonce sa participation à plusieurs conférences investisseursAug 31, 2026Other filingsEuronext
S-8 · Registration statement for employee plansAug 6, 2026Offer documentSEC
6-K · Report of a foreign issuerAug 6, 2026Current reportSEC
6-K · Report of a foreign issuerAug 6, 2026Current reportSEC
Cellectis Reports Financial Results for the Second Quarter 2026Aug 5, 2026ResultsEuronext
6-K · Report of a foreign issuerJul 30, 2026Current reportSEC
6-K/A · Report of a foreign issuer, amendedJun 26, 2026Current reportSEC
6-K · Report of a foreign issuerJun 25, 2026Current reportSEC
6-K · Report of a foreign issuerJun 25, 2026Current reportSEC
6-K · Report of a foreign issuerJun 11, 2026Current reportSEC
6-K · Report of a foreign issuerJun 9, 2026Current reportSEC
6-K · Report of a foreign issuerMay 20, 2026Current reportSEC
6-K · Report of a foreign issuerMay 20, 2026Current reportSEC
6-K · Report of a foreign issuerMay 12, 2026Current reportSEC
6-K · Report of a foreign issuerMay 11, 2026Current reportSEC
6-K · Report of a foreign issuerMay 11, 2026Current reportSEC
6-K · Report of a foreign issuerMay 4, 2026Current reportSEC
6-K · Report of a foreign issuerApr 27, 2026Current reportSEC
6-K · Report of a foreign issuerApr 13, 2026Current reportSEC
20-F · Annual reportMar 19, 2026Annual reportSEC
6-K · Report of a foreign issuerMar 19, 2026Current reportSEC
6-K · Report of a foreign issuerMar 12, 2026Current reportSEC
6-K · Report of a foreign issuerJan 8, 2026Current reportSEC
6-K · Report of a foreign issuerDec 15, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 12, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerDec 8, 2025Current reportSEC
6-K · Report of a foreign issuerDec 5, 2025Current reportSEC
6-K · Report of a foreign issuerNov 19, 2025Current reportSEC
6-K · Report of a foreign issuerNov 7, 2025Current reportSEC
6-K · Report of a foreign issuerNov 3, 2025Current reportSEC
6-K · Report of a foreign issuerOct 31, 2025Current reportSEC
6-K · Report of a foreign issuerOct 17, 2025Current reportSEC
6-K · Report of a foreign issuerOct 16, 2025Current reportSEC
6-K/A · Report of a foreign issuer, amendedOct 14, 2025Current reportSEC
6-K · Report of a foreign issuerOct 7, 2025Current reportSEC
S-8 · Registration statement for employee plansSep 12, 2025Offer documentSEC
6-K · Report of a foreign issuerAug 4, 2025Current reportSEC
6-K · Report of a foreign issuerAug 4, 2025Current reportSEC
6-K · Report of a foreign issuerJul 28, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveJul 14, 2025Other filingsSEC
CORRESP · Letter to the SECJul 9, 2025Other filingsSEC
UPLOAD · Letter from the SECJul 7, 2025Other filingsSEC
F-3 · Registration statementJul 2, 2025Offer documentSEC
6-K · Report of a foreign issuerJun 26, 2025Current reportSEC
6-K · Report of a foreign issuerJun 26, 2025Current reportSEC
6-K · Report of a foreign issuerMay 21, 2025Current reportSEC
6-K · Report of a foreign issuerMay 21, 2025Current reportSEC
6-K · Report of a foreign issuerMay 12, 2025Current reportSEC
6-K · Report of a foreign issuerMay 12, 2025Current reportSEC
6-K · Report of a foreign issuerMay 6, 2025Current reportSEC
6-K · Report of a foreign issuerApr 28, 2025Current reportSEC
6-K · Report of a foreign issuerMar 31, 2025Current reportSEC
20-F/A · Annual report, amendedMar 14, 2025Annual reportSEC
20-F · Annual reportMar 13, 2025Annual reportSEC
6-K · Report of a foreign issuerMar 7, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 24, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 30, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 24, 2025Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveJan 24, 2025Other filingsSEC
CORRESP · Letter to the SECJan 21, 2025Other filingsSEC
UPLOAD · Letter from the SECJan 16, 2025Other filingsSEC
F-3 · Registration statementJan 15, 2025Offer documentSEC
S-8 · Registration statement for employee plansJan 15, 2025Offer documentSEC
6-K · Report of a foreign issuerDec 10, 2024Current reportSEC
6-K · Report of a foreign issuerNov 5, 2024Current reportSEC
6-K · Report of a foreign issuerNov 4, 2024Current reportSEC
6-K · Report of a foreign issuerOct 30, 2024Current reportSEC
6-K · Report of a foreign issuerOct 22, 2024Current reportSEC
6-K/A · Report of a foreign issuer, amendedSep 11, 2024Current reportSEC
6-K · Report of a foreign issuerSep 3, 2024Current reportSEC
6-K · Report of a foreign issuerAug 26, 2024Current reportSEC
6-K · Report of a foreign issuerAug 7, 2024Current reportSEC
6-K · Report of a foreign issuerAug 6, 2024Current reportSEC
6-K · Report of a foreign issuerAug 1, 2024Current reportSEC
6-K · Report of a foreign issuerJul 25, 2024Current reportSEC
6-K · Report of a foreign issuerJun 28, 2024Current reportSEC
6-K · Report of a foreign issuerJun 28, 2024Current reportSEC
6-K · Report of a foreign issuerJun 20, 2024Current reportSEC
6-K · Report of a foreign issuerJun 12, 2024Current reportSEC
6-K · Report of a foreign issuerJun 4, 2024Current reportSEC
6-K · Report of a foreign issuerMay 29, 2024Current reportSEC
6-K · Report of a foreign issuerMay 28, 2024Current reportSEC
6-K · Report of a foreign issuerMay 28, 2024Current reportSEC
6-K · Report of a foreign issuerMay 28, 2024Current reportSEC
6-K · Report of a foreign issuerMay 24, 2024Current reportSEC
SC 13D/A · Big-stake notice, amendedMay 21, 2024Big-stake noticeSEC
6-K · Report of a foreign issuerMay 6, 2024Current reportSEC
6-K · Report of a foreign issuerMay 2, 2024Current reportSEC
20-F · Annual reportApr 29, 2024Annual reportSEC
6-K · Report of a foreign issuerApr 22, 2024Current reportSEC
6-K · Report of a foreign issuerApr 10, 2024Current reportSEC
6-K · Report of a foreign issuerApr 8, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
6-K · Report of a foreign issuerJan 16, 2024Current reportSEC
6-K · Report of a foreign issuerDec 22, 2023Current reportSEC
6-K · Report of a foreign issuerDec 22, 2023Current reportSEC
6-K · Report of a foreign issuerDec 5, 2023Current reportSEC
SC 13G/A · Big-stake notice, amendedDec 5, 2023Big-stake noticeSEC
6-K · Report of a foreign issuerNov 17, 2023Current reportSEC
6-K · Report of a foreign issuerNov 17, 2023Current reportSEC
SC 13D/A · Big-stake notice, amendedNov 16, 2023Big-stake noticeSEC
6-K · Report of a foreign issuerNov 15, 2023Current reportSEC
SC 13D/A · Big-stake notice, amendedNov 13, 2023Big-stake noticeSEC
SC 13D · Big-stake noticeNov 9, 2023Big-stake noticeSEC
6-K · Report of a foreign issuerNov 9, 2023Current reportSEC
6-K · Report of a foreign issuerNov 6, 2023Current reportSEC
6-K · Report of a foreign issuerNov 6, 2023Current reportSEC
6-K · Report of a foreign issuerNov 2, 2023Current reportSEC
6-K · Report of a foreign issuerNov 1, 2023Current reportSEC
6-K · Report of a foreign issuerNov 1, 2023Current reportSEC
20-F/A · Annual report, amendedOct 31, 2023Annual reportSEC
6-K · Report of a foreign issuerOct 31, 2023Current reportSEC
6-K · Report of a foreign issuerOct 31, 2023Current reportSEC
6-K · Report of a foreign issuerOct 24, 2023Current reportSEC
6-K · Report of a foreign issuerOct 12, 2023Current reportSEC
6-K · Report of a foreign issuerSep 27, 2023Current reportSEC
6-K/A · Report of a foreign issuer, amendedSep 5, 2023Current reportSEC
S-8 · Registration statement for employee plansAug 7, 2023Offer documentSEC
6-K · Report of a foreign issuerAug 7, 2023Current reportSEC
6-K · Report of a foreign issuerAug 7, 2023Current reportSEC
6-K · Report of a foreign issuerAug 3, 2023Current reportSEC
6-K · Report of a foreign issuerJul 27, 2023Current reportSEC
6-K · Report of a foreign issuerJul 12, 2023Current reportSEC
6-K · Report of a foreign issuerJun 29, 2023Current reportSEC
6-K · Report of a foreign issuerJun 28, 2023Current reportSEC
6-K · Report of a foreign issuerJun 9, 2023Current reportSEC
6-K · Report of a foreign issuerJun 5, 2023Current reportSEC
SC 13D/A · Big-stake notice, amendedJun 1, 2023Big-stake noticeSEC
6-K · Report of a foreign issuerMay 31, 2023Current reportSEC
6-K · Report of a foreign issuerMay 22, 2023Current reportSEC
6-K · Report of a foreign issuerMay 17, 2023Current reportSEC
6-K · Report of a foreign issuerMay 12, 2023Current reportSEC
6-K · Report of a foreign issuerMay 11, 2023Current reportSEC
6-K · Report of a foreign issuerMay 4, 2023Current reportSEC
6-K · Report of a foreign issuerMay 2, 2023Current reportSEC
6-K · Report of a foreign issuerApr 27, 2023Current reportSEC
6-K · Report of a foreign issuerApr 24, 2023Current reportSEC
6-K · Report of a foreign issuerApr 17, 2023Current reportSEC
6-K · Report of a foreign issuerApr 11, 2023Current reportSEC
6-K · Report of a foreign issuerApr 4, 2023Current reportSEC
6-K · Report of a foreign issuerMar 14, 2023Current reportSEC
20-F · Annual reportMar 14, 2023Annual reportSEC
6-K · Report of a foreign issuerMar 8, 2023Current reportSEC
6-K · Report of a foreign issuerMar 6, 2023Current reportSEC
6-K · Report of a foreign issuerMar 1, 2023Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
6-K · Report of a foreign issuerFeb 8, 2023Current reportSEC
6-K · Report of a foreign issuerFeb 7, 2023Current reportSEC
6-K · Report of a foreign issuerFeb 7, 2023Current reportSEC
424B5 · ProspectusFeb 3, 2023Offer documentSEC
6-K · Report of a foreign issuerFeb 3, 2023Current reportSEC
6-K · Report of a foreign issuerFeb 3, 2023Current reportSEC
6-K · Report of a foreign issuerFeb 2, 2023Current reportSEC
424B5 · ProspectusFeb 2, 2023Offer documentSEC
6-K · Report of a foreign issuerJan 20, 2023Current reportSEC
SC 13G/A · Big-stake notice, amendedJan 18, 2023Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedJan 17, 2023Big-stake noticeSEC
6-K · Report of a foreign issuerJan 17, 2023Current reportSEC
6-K · Report of a foreign issuerJan 17, 2023Current reportSEC
FWP · Free writing prospectusJan 4, 2023Offer documentSEC
6-K · Report of a foreign issuerJan 4, 2023Current reportSEC
6-K · Report of a foreign issuerJan 4, 2023Current reportSEC
424B5 · ProspectusJan 4, 2023Offer documentSEC
6-K · Report of a foreign issuerJan 4, 2023Current reportSEC
6-K · Report of a foreign issuerJan 4, 2023Current reportSEC
6-K · Report of a foreign issuerDec 29, 2022Current reportSEC
6-K · Report of a foreign issuerDec 28, 2022Current reportSEC
6-K · Report of a foreign issuerDec 22, 2022Current reportSEC
6-K · Report of a foreign issuerDec 13, 2022Current reportSEC
6-K · Report of a foreign issuerDec 1, 2022Current reportSEC
6-K · Report of a foreign issuerNov 10, 2022Current reportSEC
6-K · Report of a foreign issuerNov 10, 2022Current reportSEC
6-K · Report of a foreign issuerNov 3, 2022Current reportSEC
6-K · Report of a foreign issuerNov 3, 2022Current reportSEC
6-K · Report of a foreign issuerNov 3, 2022Current reportSEC
SC 13D/A · Big-stake notice, amendedNov 1, 2022Big-stake noticeSEC
6-K · Report of a foreign issuerOct 27, 2022Current reportSEC
6-K · Report of a foreign issuerOct 11, 2022Current reportSEC
S-8 · Registration statement for employee plansOct 6, 2022Offer documentSEC
6-K · Report of a foreign issuerOct 5, 2022Current reportSEC
6-K · Report of a foreign issuerSep 28, 2022Current reportSEC
6-K · Report of a foreign issuerSep 22, 2022Current reportSEC

This page holds 200 of 547 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Cellectis S.A.’s releases

Common shares
72,732,781
Fully diluted
72,732,781

Fully diluted

LineShares
Common shares72,732,781

Share count over time

CountShares
Nov 22, 202672,732,781

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
B Group, Inc.3.28MUS$4.96MSep 30, 2026
Long Focus Capital Management, LLC2.74MUS$4.14MSep 30, 2026
UBS2.65MUS$4MSep 30, 2026
BlackRock246KUS$372KSep 30, 2026
Nomura227KUS$343KSep 30, 2026
Morgan Stanley86,366US$130KSep 30, 2026
LPL Financial LLC85,595US$129KSep 30, 2026
BNP Paribas37,500US$56,625Sep 30, 2026
Walleye Partners, LLC35,000US$52,850Sep 30, 2026
Susquehanna29,989US$45,283Sep 30, 2026
All 30 holders
HolderSharesValueAs of
Delaney Dennis R24,000US$36,240Sep 30, 2026
Hrt Financial LP23,679US$35,000Sep 30, 2026
Rhumbline Advisers14,303US$21,593Sep 30, 2026
Two Sigma13,566US$20,485Sep 30, 2026
Harbour Investments, Inc.4,500US$6,795Sep 30, 2026
National Bank Of Canada3,600US$5,400Sep 30, 2026
Tower Research Capital LLC (TRC)3,588US$5,418Sep 30, 2026
Wells Fargo3,150US$4,757Sep 30, 2026
Pinnacle Financial Group, Inc.1,500US$2,265Sep 30, 2026
Atlantic Union Bankshares Corp1,500US$2,265Sep 30, 2026
Allworth Financial LP500US$755Sep 30, 2026
POM Investment Strategies, LLC495US$747Sep 30, 2026
JPMorgan166US$244Sep 30, 2026
Fidelity100US$151Sep 30, 2026
Osaic Holdings, Inc.100US$147Sep 30, 2026
Larson Financial Group LLC75US$113Sep 30, 2026
EverSource Wealth Advisors, LLC13US$20Sep 30, 2026
Inspire Investing, LLC6US$9Sep 30, 2026
Citigroup Inc1US$2Sep 30, 2026
Barclays1US$2Sep 30, 2026

Funds

HolderSharesValueAs of
Nomura Healthcare Fund227KUS$681KJun 30, 2026
iShares Biotechnology ETF223KUS$669KJun 30, 2026

Big stakes

StakeStakeSharesDateFiling
AstraZeneca PLC44.00%44MJan 23, 2025Schedule 13D
Bpifrance Participations S.A.10.00%9.56MOct 28, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Adrian KilcoyneChief Medical Officer · Since at least May 12, 2026
André ChoulikaChief Executive Officer & Director · Since at least Sep 14, 2026
Arthur StrilChief Financial Officer & Chief Business Officer · Since at least Oct 27, 2026
David SourdiveExecutive Vice President CMC & Manufacturing and Director · Since at least May 29, 2026
Jean-Pierre GarnierChairman of the Board of Directors - Director · Since at least May 29, 2026
Kyung Nam-WortmanExecutive Vice President, Chief Human Resources Officer · Since at least Nov 5, 2026
Marie-Bleuenn TerrierGeneral Counsel · Since at least Nov 5, 2026
Patricia Sosa NavarroChief of Staff to the CEO · Since at least Oct 27, 2026
Philippe DuchateauChief Scientific Officer · Since at least Nov 5, 2026
Stephan ReynierChief Regulatory and Pharmaceutical Compliance Officer · Since at least Nov 5, 2026
All 11 people
PersonSeat
Steve DoaresSenior Vice President, US Manufacturing and Site Head · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Cellectis S.A.